3-MeO-PCP CAS # 91164-58-8 or 3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug which, as a research chemical, has been sold online. To investigate the structure-activity relationship of phencyclidine derivatives, the compound was first synthesized in 1979. The operation of 3-MeO-PCP in humans was not identified until 1999, when the pseudonym John Q was used by a chemist. Beagle wrote that 3-MeO-PCP with equivalent potency was qualitatively similar to PCP. 3-MeO-PCP has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP, and binds to the NMDA receptor with greater affinity than PCP. While 3-MeO-PCP is often identified as having opioid or dopaminergic activity, data showing that 3-MeO-PCP is a potent and selective NMDA receptor ligand without significant affinity for the μ-opioid receptor or dopamine transporter contradicts this assumption. The less potent dissociative 4-MeO-PCP was followed by 3-MeO-PCP and first became available as a research chemical in 2011.

The white crystalline solid with a melting point of 204-205 ° C is 3-MeO-PCP hydrochloride

For the NMDA receptor, 3-MeO-PCP has a Ki of 20 nM, 216 nM for the serotonin transporter and 42 nM for the sigma1 receptor.